27 results about "Amphetamine use" patented technology

The invention discloses application of lycium barbarum polysaccharide in preparation of a medicine for inhibiting methylamphetamine-induced nerve injury, and relates to the technical field of biological medicines. It is found and proved that lycium barbarum polysaccharide can inhibit methylamphetamine-induced nerve injury, and the effect is remarkable. From the aspect of cell survival, the survival rate of the microglial cells pretreated by the lycium barbarum polysaccharide after METH stimulation is obviously improved. In the molecular mechanism, the lycium barbarum polysaccharide can effectively lower the protein expression level of the METH-induced pyroptosis marker, the content of inflammatory factors IL-1beta and IL-18 can be reduced, and the release of lactic dehydrogenase is reduced. The result shows that the lycium barbarum polysaccharide can alleviate inflammatory response by inhibiting NLRP3 / ASC pathway mediated microglial cell pyroptosis, thereby inhibiting METH-induced nerve injury. The invention provides a new direction for developing METH neurotoxicity intervention medicines.

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

The application belongs to the technical field of water treatment, and particularly relates to a new psychoactive substance adsorbent and application thereof. The preparation method of the adsorbent comprises the following steps: (1) mixing and reacting activated shrimp shell biomass and ferroferric oxide nano magnetic material, drying, and pyrolyzing to obtain Fe3O4@BC; (2) mixing and reacting Fe3O4@BC and ZIF-8 to obtain Fe3O4@BC@ZIF-8; and (3) mixing and reacting a eutectic solvent with Fe3O4@BC@ZIF-8 to obtain the new psychoactive substance adsorbent. The adsorbent has strong adsorption capacity for 4-methyl methcathinone, methcathinone, amphetamine, methamphetamine and ephedrine, and the adsorption efficiency can reach 98% for 4-methyl methcathinone in particular.

The invention relates to a polymeric nanomaterial that has specific affinity for MeA (methamphetamine) or AMP (amphetamine-derived synthetic drugs) and can exist at the nanoscale, as well as to the synthesis method thereof.

The present application relates to a kind of drug rapid detection method, equipment and medium based on photonic crystal image, comprising: image pre-processing, to locate the position of photonic crystal in image and cut image, so that only photonic crystal is left in the image after cutting;Extract the color feature vector of the photonic crystal, and carry out dimension reduction processing;The color feature vector after dimension reduction is converted, identified and compared based on support vector machine, and the drug identification of the to-be-measured body fluid is completed.The present application is based on the color difference of different drugs and photonic crystal after reaction, judges what kind of drug, such as amphetamine, pseudoephedrine, chloroephedrine, methylcathinone or methamphetamine, contained in the to-be-measured liquid by comparing with standard spectrum, fast, low cost, mass detection, low equipment cost.

The application provides a compound composition for preventing and treating motion sickness and a preparation method thereof, the compound composition comprises the following raw materials in parts by weight: dimenhydrinate 2-6 parts, dextroamphetamine 0.2-0.6 parts, ginger 20-50 parts, dried tangerine or orange peel 10-20 parts, privet fruit 8-15 parts, tribulus terrestris 8-15 parts, rhizoma alocasia 5-12 parts, pachystachys jamaicensis 8-15 parts, daya flower 5-10 parts, litsea cubeba 3-8 parts, kaempferia 3-8 parts, ipomoea alba 5-10 parts, menthol 0.5-3 parts; the compound composition of the application realizes the enhancement of the anti-motion effect and the offset of the side effects, and especially significantly reduces the drowsiness caused by dimenhydrinate and the potential risk of excessive nerve excitement of dextroamphetamine.

This invention provides a method for constructing a donor-acceptor type perylene diimide-based porous conjugated polymer probe and detecting methamphetamine and amphetamine solutions. The method synthesizes donor-acceptor type perylene diimide-based porous conjugated polymer probes with different topologies by combining an electron acceptor perylene diimide derivative and an electron donor aggregation-induced emission fluorophore via a succinate coupling reaction. When used for the detection of methamphetamine and amphetamine, this system exhibits a clear ratiometric fluorescence response, with the fluorescence color gradually changing from yellow-green to orange and orange-red, demonstrating a significant ratiometric fluorescence response. It features fast response speed, high detection sensitivity, good selectivity, and no interference from other common structurally and property-similar substances, enabling the differentiation and identification of methamphetamine and amphetamine.

It relates to an oral pharmaceutical solution comprising from 1 mg / ml to 40 mg / ml of a pharmaceutical acceptable salt of lisdexamfetamine, water, a buffer and a polysaccharide wherein the pH of the solution is from 5.0 to 8.5, as well as to its preparation process. The oral pharmaceutical solution is useful for treating attention-deficit and hyperactivity disorder.

The present application belongs to the technical field of drug detection method, and particularly relates to a method for detecting drugs in atmospheric environment samples, comprising the following steps: using the adsorption material of a gas sampling instrument to adsorb the drugs in the gas; after the material adsorbs the drugs, using ultrasonic extraction in an organic solvent or a high-temperature heating method to resolve the drugs; and using high-sensitivity mass spectrometry, molecular immunocolloidal gold or fluorescence method to detect the resolved drugs. The detection method can qualitatively and quantitatively detect the drugs in the atmosphere, and is also suitable for detecting the drugs in the exhaled gas of drug users, and contains new psychoactive drugs such as amphetamines, opioids and synthetic cannabis.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients. In another aspect, tryptamine compositions described herein enhance neuroplasticity by promoting neuronal branching through the formation of neurites (i.e., neurite outgrowth) and neurite elongation (i.e., increasing neurite length).

The present invention is directed to chemical compositions of matter, and in particular a MDMA class of analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a basic or modified side chain.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

Abstract Disclosed are d-amphetamine compounds and compositions comprising at least one organic acid covalently bound to d-amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed. Abstract

The invention relates to a polydimethylsiloxane-reduced graphene oxide composite coating solid-phase extraction fiber as well as a preparation method and application thereof, and belongs to the technical field of sample pretreatment and trace analysis. Aiming at the problems of poor conductivity and insufficient coating stability of the traditional solid-phase microextraction fiber, a PDMS-rGO composite coating is constructed by a three-step method, graphene oxide is reduced by ascorbic acid and calcined to form a loose multi-layer structure, PDMS is loaded by a sol-gel method, and the coating fiber with the thickness of 40-60 microns and the conductivity of 30-35 k omega is obtained. In combination with an electrochemical enhanced solid-phase microextraction technology, the fiber is used for efficiently extracting amphetamine stimulants, and in combination with an online derivatization-gas chromatography-nitrogen and phosphorus detector, trace detection is realized. Experiments show that the composite coating has high affinity of PDMS and excellent conductivity of rGO, the thermal stability is improved to 800 DEG C or above, and the mechanical durability reaches 150 times of cyclic extraction. And a high-sensitivity solution is provided for rapid screening of amphetamine substances in a biological matrix.

This invention provides a donor-acceptor type perylene diimide-based porous conjugated polymer sensing membrane for distinguishing between methamphetamine and amphetamine atmospheres. The membrane is prepared by spin-coating a homogeneous mixture of the donor-acceptor type perylene diimide porous conjugated polymer, polystyrene, and a solvent. When used for the detection of methamphetamine and amphetamine atmospheres, the system exhibits a significant differential ratio fluorescence response, achieving quantitative and differential detection of methamphetamine and amphetamine atmospheres in the ranges of 0-600 ppm and 0-1500 ppm, respectively. It offers advantages such as fast response, simple detection process, high sensitivity, and good selectivity, without interference from other common structurally and property-similar substances. This provides a research solution for the on-site identification and differentiation of hazardous chemicals with similar structures and properties.

The invention provides a non-distillative process for manufacturing amphetamine and substituted amphetamines, comprising obtaining a highly pure phosphoramidate compound, converting the highly pure phosphoramidate compound to an amphetamine sulfate compound, concentrating the amphetamine sulfate compound in isopropanol, and then salting out the amphetamine compound directly to obtain an amphetamine salt, the amphetamine salt selected from amphetamine saccharate, amphetamine sulfate, amphetamine aspartate, alkyl-amphetamine saccharate, alkyl-amphetamine sulfate, alkyl-amphetamine aspartate, aryl-amphetamine saccharate, aryl-amphetamine sulfate, aryl-amphetamine aspartate, and mixtures thereof.

The invention relates to a preparation method of a ridexamphetamine dimesylate dispersible tablet. The preparation method comprises the following steps: carrying out dry mixing on ridexamphetamine dimesylate, a diluent, an adhesive and an antistatic agent to form a dry-mixed blend; performing intermediate particulate blending on a filler, a buffer, a disintegrant, and a sweetener to form an intermediate particulate blend; adding and blending the dry blend and the intermediate particulate blend to form an intermediate pharmaceutical blend; lubricating the intermediate drug blend with a lubricant to form standby compressed drug particles; and compressing the standby compressed medicine particles to form the ridexamphetamine dimesylate dispersible tablet.

Methods and compositions, e.g., compositions for intravenous administration, comprising dextroamphetamine and / or lisdexamfetamine for use in reversal of dexmedetomidine sedation.

The application belongs to the field of environmental sample detection, and discloses a method for simultaneously detecting 20 kinds of benzene amphetamine, piperazine and benzodiazepine psychoactive substances in water bodies. The method simultaneously extracts and detects 20 kinds of benzene amphetamine, piperazine and benzodiazepine psychoactive substances in water bodies by using dispersion liquid liquid microextraction and high performance liquid chromatography mass spectrometry. The average recovery rate of the 20 target compounds is 71.5% to 108%, the standard deviation is 0.7% to 4.8%, the detection limit is 1.5 to 10.5 ng / L, and the quantitative limit is 6.0 to 42.2 ng / L. The method has high recovery rate, high sensitivity and good repeatability, and can be used for detecting benzene amphetamine, piperazine and benzodiazepine psychoactive substances in water bodies.

Abstract Disclosed are d-amphetamine compounds of formula (I) and compositions comprising at least one organic acid covalently bound to d-amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed. Abstract

The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence / abuse / addiction and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

The invention discloses a (+)-naltrexone derivative and an application of the (+)-naltrexone derivative in treatment of amphetamine drug addiction. Compared with the (+)-naltrexone, the (+)-naltrexone derivative has the advantages that the anti-neuroinflammatory activity is obviously improved, the anti-inflammatory activity of most of the derivatives is improved by 1000 times or more, and the anti-inflammatory activity of the derivative with the highest activity is even improved by 10000 times or more.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

The invention relates to a compound and application of the compound in reduction of magical risk caused by psychotropic drugs. The invention provides a compound, and a composition of pharmaceutically acceptable salt, racemate, enantiomer, solvate, hydrate, crystal form or eutectic of the compound. The compound is applied to preparation of a medicine for reducing the risk of magical risk caused by psychotropic drugs, and the psychotropic drugs are dimethoxytoluene propylamine. The invention synthesizes a compound which is used as a weak partial agonist of 5-HT2AR, can enhance the activation of DOM and 5-HT on a beta-arrestin2 pathway, has no influence on a G alpha q / 11 pathway, and shows special pharmacological properties.